Results 321 to 330 of about 176,622 (333)

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Lancet, The, 2007
Alain Ravaud, Sergio Bracarda, C?zary A Szczylik   +2 more
exaly  

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Lancet, The, 2016
Gérard Zalcman, Julien Mazieres, Laurent Greillier   +2 more
exaly  

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Lancet Respiratory Medicine,the, 2019
Makoto Nishio, Federico Cappuzzo, Daniil Stroyakovskiy   +2 more
exaly  

Bevacizumab

Reactions Weekly, 2007
openaire   +1 more source

Bevacizumab

Reactions Weekly, 2014
openaire   +1 more source

Bevacizumab in neoadjuvant chemotherapy increases the pathological complete response rate in patients with triple‐negative breast cancer

Ca-A Cancer Journal for Clinicians, 2014
exaly  

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Lancet Oncology, The, 2015
Chiara Cremolini, Fotios Loupakis, Sara Lonardi   +2 more
exaly  

Bevacizumab

Reactions Weekly
openaire   +1 more source

Small reduction in quality of life seen with bevacizumab maintenance in patients with ovarian cancer

Ca-A Cancer Journal for Clinicians, 2013
exaly  

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Nature Communications, 2016
Johanna C Bendell, Konstanty Korski, Suzanne Jones   +2 more
exaly